Originally published by our sister publication, Clinical Oncology News.
By Dave Doolittle
The FDA approved a fixed-dose combination of the programmed death-1–blocking antibody nivolumab and relatlimab-rmbw, a lymphocyte activation gene-3–blocking antibody, to treat patients aged 12 years and older with unresectable or metastatic melanoma.
Patients treated with the combination, called Opdualag (Bristol Myers Squibb), showed a statistically significant improvement in progression-free